Neuren Pharmaceuticals Ltd
ASX:NEU
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.72
22.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
NEU
stock under the Base Case scenario is
12.4
AUD.
Compared to the current market price of 18.64 AUD,
Neuren Pharmaceuticals Ltd
is
Overvalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Neuren Pharmaceuticals Ltd.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Regulatory uncertainty surrounding Neuren’s lead candidate trofinetide—particularly in complex neurological indications—poses a significant risk, as any delays in approvals or unfavorable trial data could derail the company’s revenue timeline and shake investor confidence.
Heavy dependence on commercialization partners, such as Acadia Pharmaceuticals for U.S. marketing, heightens counterparty risk. If Acadia or any future partners fail to execute commercially or deprioritize joint programs, Neuren’s growth prospects may be severely constrained.
Limited diversification in the pipeline, focused primarily on rare pediatric neurological disorders, increases Neuren’s vulnerability to setbacks. Negative trial outcomes or new competitive treatments within the same niches could rapidly erode its market opportunity.
Trofinetide’s potential first-mover advantage in Rett syndrome offers a pathway to regulatory approval and commercial success, creating a strong, near-term revenue stream if upcoming data and launches proceed favorably.
Neuren’s other pipeline candidate, NNZ-2591, addresses diverse neurodevelopmental indications (e.g., Phelan-McDermid, Angelman, and Pitt Hopkins syndromes), offering a broad, long-term growth runway if proof-of-concept studies confirm efficacy and safety.
Robust partnerships with established pharmaceutical players, alongside targeted focus on severe neurological disorders, strengthens Neuren’s ability to navigate complex clinical development and expand global market reach efficiently.
Revenue & Expenses Breakdown
Neuren Pharmaceuticals Ltd
Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd
| Current Assets | 320.2m |
| Cash & Short-Term Investments | 299.5m |
| Receivables | 20.7m |
| Non-Current Assets | 11m |
| PP&E | 25k |
| Other Non-Current Assets | 11m |
| Current Liabilities | 7.9m |
| Accounts Payable | 6.7m |
| Other Current Liabilities | 1.3m |
| Non-Current Liabilities | 55k |
| Other Non-Current Liabilities | 55k |
Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Neuren Pharmaceuticals Ltd
|
Revenue
|
228.7m
AUD
|
|
Operating Expenses
|
-34.8m
AUD
|
|
Operating Income
|
193.9m
AUD
|
|
Other Expenses
|
-44.8m
AUD
|
|
Net Income
|
149.1m
AUD
|
NEU Profitability Score
Profitability Due Diligence
Neuren Pharmaceuticals Ltd's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
Score
Neuren Pharmaceuticals Ltd's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
NEU Solvency Score
Solvency Due Diligence
Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NEU Price Targets Summary
Neuren Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
NEU
is 26.97 AUD
with a low forecast of 21.41 AUD and a high forecast of 33.6 AUD.
Dividends
Current shareholder yield for
NEU is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NEU
stock under the Base Case scenario is
12.4
AUD.
Compared to the current market price of 18.64 AUD,
Neuren Pharmaceuticals Ltd
is
Overvalued by 33%.